A comprehensive presentation on GMP systems and integration. This includes validations, vendor qualification, preventative maintenance, audits, CAPA, and utilization of system results.
Regulatory inspections have had a significant impact on the number of drug shortages and companies facing adverse regulatory actions.
Review of the inspection trends can be useful in assessing the regulatory status of your own company and help aid in the preparation for upcoming inspections. This session from IVT's Contamination and Control Week provides an in-depth, practical look at some of the recent Warning Letters and discusses current trends.
In this presentation from, Janeen Santorosa discusses the best practices for harmonization of GMP auditing, domestic and international regulations for supplier auditing, integration of risk-based practices, and supplier audit practice tools.
This workshop examines the approach to Continued Process Verification and demonstrating that your product and process are operating in a state of control and continue to do so over the life of the product. Without any prior coordination, the theme was elaborated by the afternoon speakers once the conference itself was underway. The concept of “step up step down” for adjusting the level of product scrutiny both for process parameters monitoring and for sampling and testing quality attributes was explored and developed.
In this presentation from the Institute of Validation Technology's Life Sciences Aseptic Processing, Kim Van Antwerpen discusses collecting environmental data, methods for trending, and interpreting and sharing environmental monitoring data.
This presentation from the Institute of Validation Technology's first annual Validation and cGMP Compliance Week Singapore discusses the obstacles to quality such, the key components to improve quality, and the tools for strategic teamwork.
In this presentation from IVT's GMP Week, Journal of Validation Technology Editor-in-Chief, Paul Pluta, Ph.D., asks "can compliance be improved by using quality by design [QbD] concepts?" Pluta discussed the QbD application, development of validation master plans, and the lifecycle approach to process validation. Furthermore, he discusses how to incorporate these essential parts of the validation process to implement effective, and efficient, compliance by design into the quality system.
Regulatory inspections have had a significant impact on the number of drug shortages and companies facing adverse regulatory actions.
Review of the inspection trends can be useful in assessing the regulatory status of your own company and help aid in the preparation for upcoming inspections. This session from IVT's Contamination and Control Week provides an in-depth, practical look at some of the recent Warning Letters and discusses current trends.
In this presentation from, Janeen Santorosa discusses the best practices for harmonization of GMP auditing, domestic and international regulations for supplier auditing, integration of risk-based practices, and supplier audit practice tools.
This workshop examines the approach to Continued Process Verification and demonstrating that your product and process are operating in a state of control and continue to do so over the life of the product. Without any prior coordination, the theme was elaborated by the afternoon speakers once the conference itself was underway. The concept of “step up step down” for adjusting the level of product scrutiny both for process parameters monitoring and for sampling and testing quality attributes was explored and developed.
In this presentation from the Institute of Validation Technology's Life Sciences Aseptic Processing, Kim Van Antwerpen discusses collecting environmental data, methods for trending, and interpreting and sharing environmental monitoring data.
This presentation from the Institute of Validation Technology's first annual Validation and cGMP Compliance Week Singapore discusses the obstacles to quality such, the key components to improve quality, and the tools for strategic teamwork.
In this presentation from IVT's GMP Week, Journal of Validation Technology Editor-in-Chief, Paul Pluta, Ph.D., asks "can compliance be improved by using quality by design [QbD] concepts?" Pluta discussed the QbD application, development of validation master plans, and the lifecycle approach to process validation. Furthermore, he discusses how to incorporate these essential parts of the validation process to implement effective, and efficient, compliance by design into the quality system.
Process Validation Presentation from BioTechLogicPeter Dellva
Exploring Manufacturing Process Validation - BioTechLogic, Inc. is a biopharmaceutical manufacturing and CMC consulting firm with strategic and practical/hands-on experience that helps clients bring their products to market quickly and successfully by augmenting and optimizing an organization’s technical, manufacturing, analytical, and regulatory resources.
Our technical expertise resides in a wide range of biological and oligonucleotide products including recombinant proteins, vaccines and blood products. Through the combined expertise and knowledge of our staff, we have developed proven methodologies and approaches for providing reliable and dependable services in the following areas:
Process Development and Quality by Design (QbD) including:
Design of Experiments (DOE)
Development Reports
Critical Process Parameter Evaluation
Technology Implementation, Transfer and Scale-up
On-site third party contract manufacturing support
BioAnalytical Services
Process Validation
Biotechnology Project Management
Quality Assurance
Regulatory Submissions
PAI Inspection Readiness (FDA Pre-Approval Inspection Readiness)
Pharmaceutical Validation, its scope and types. Validation Team. validation Master plan. Validation protocols. Elements of Validation. Approaches of Validation. Dosage form Validation along with example of Validation of Tablet Dosage form.
Pharmaceutical Good Manufacturing PracticesPharmaceutical
When you are in healthcare, Then GMP is must. Regulatory philosophy for product Quality have been changed from "Quality by Testing QbT" to "Quality by Design QbD". Quality is to be built in product and that only can be done by GMP.
This full day presentation gives an overview of the process validation lifecycle approach, the FDA PV Guidance, the lifecycle approach to cleaning validation, equipment qualification, and validation quality systems.
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...TGA Australia
An overview of regulatory requirements introduced as part of the new PIC/s PE009-13 Guide to Good Manufacturing Practice, specifically outlining impact on micro laboratories. Also, a summary of the new PI041-1 Data Integrity Guidance will be provided with a particular focus of Data Integrity in the laboratory
Process Validation Presentation from BioTechLogicPeter Dellva
Exploring Manufacturing Process Validation - BioTechLogic, Inc. is a biopharmaceutical manufacturing and CMC consulting firm with strategic and practical/hands-on experience that helps clients bring their products to market quickly and successfully by augmenting and optimizing an organization’s technical, manufacturing, analytical, and regulatory resources.
Our technical expertise resides in a wide range of biological and oligonucleotide products including recombinant proteins, vaccines and blood products. Through the combined expertise and knowledge of our staff, we have developed proven methodologies and approaches for providing reliable and dependable services in the following areas:
Process Development and Quality by Design (QbD) including:
Design of Experiments (DOE)
Development Reports
Critical Process Parameter Evaluation
Technology Implementation, Transfer and Scale-up
On-site third party contract manufacturing support
BioAnalytical Services
Process Validation
Biotechnology Project Management
Quality Assurance
Regulatory Submissions
PAI Inspection Readiness (FDA Pre-Approval Inspection Readiness)
Pharmaceutical Validation, its scope and types. Validation Team. validation Master plan. Validation protocols. Elements of Validation. Approaches of Validation. Dosage form Validation along with example of Validation of Tablet Dosage form.
Pharmaceutical Good Manufacturing PracticesPharmaceutical
When you are in healthcare, Then GMP is must. Regulatory philosophy for product Quality have been changed from "Quality by Testing QbT" to "Quality by Design QbD". Quality is to be built in product and that only can be done by GMP.
This full day presentation gives an overview of the process validation lifecycle approach, the FDA PV Guidance, the lifecycle approach to cleaning validation, equipment qualification, and validation quality systems.
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...TGA Australia
An overview of regulatory requirements introduced as part of the new PIC/s PE009-13 Guide to Good Manufacturing Practice, specifically outlining impact on micro laboratories. Also, a summary of the new PI041-1 Data Integrity Guidance will be provided with a particular focus of Data Integrity in the laboratory
Validation.
Validation is establishing documented evidence which provides a high degree of assurances that a specific process or equipment will consistently produce a product or result meeting its predetermined specifications and quality attributes”.
A system must be qualified to operate in a validated process
The results of analytical procedures should be:
— reliable
— accurate
— reproducible
The characteristics that should be considered during validation of analytical methods are:
— specificity
— linearity
— range
— accuracy
— precision
— detection limit
— quantitation limit
— robustness
Qualification and Validation have big Weightage in the Regulatory Compliance and GMP. Qualification and Validation only can guarantee about the Product Safety, Integrity, Strength, Purity and Quality assurance.
Pharmaceutical Validation: Role in Phamaceutical Industrykaunainfathema1
This is a brief presentation on various concepts under Pharamaceutical Validation including its importance, scope, history, authorities, types of validation, VMP; along with the ICH and WHO Guidelines to be followed for Calibration of Equipments.
It is the documented act of proving that any procedure, process, equipment, material, activity or system actually leads to the expected result.
It is the confirmation by examination and the provision of objective evidence that the particular requirements for a specific intended use are fulfilled.
In this presentation from IVT's 4th Annual Validation Week EU, Paul Pluta, discussed the differences between the traditional approach to cleaning validation and the lifecycle approach, applicable regulatory guidance, current industry trends, the necessary phases of the lifecycle approach (design and definition, cycle development, validation, and implementation), how to continously monitor the process, change control, and common obstacles to compliance.
This session from the Institute of Validation Technology's 14th Annual CSV Conference looks at B. Braun’s journey in moving from an in-house validated training tracking system to learning management in the cloud.
In this session from the Institute of Validation Technology's Validation Week Europe, Kurtis Epp and John Kandl discuss how to implement QbD to all three stages of process validation.
This session from the Institute of Validation Technology's Contamination and Control Week discusses regulatory expectations and industry drivers for aseptic cleaning and environmental monitoring, regulatory expectations for cleanrooms, and current FDA and EU expectations during inspection of sterile and aseptic operations.
The Validation Master Plan is a a valuable opportunity to provide an overview of your company’s validation process, including organization structure, content, and planning.
Regulatory guidelines on stability testing are mainly designed to address studies that will be applied to support NDAs. However, in any pharmaceutical development program, a number of other stability studies are also required, for example, to help select appropriate formulations and to support regulatory applications for clinical programs. This session from the Institute of Validation Technology's Stability Programs Forum outlines a number of examples of early development stability studies.
This presentation from IVT's 4th Annual reviews what to do when you have an exception, critical vs. non-critical exceptions, and learning how to prevent exceptions.
This presentation from IVT's 4th Annual Validation Week Europe provided a thorough explanation of developing a gap analysis, areas in validation that are issues of concern, and FDA expectations of a manufacturer's gap analysis.
In this presentation from Validation Week Europe, Karen Ginsbury discusses the rigors, preparations, strategies, and the do's and the don't of the FDA Inspection process.
This presentation from IVT's 2nd Annual Validation Week Canada covers the 2011 FDA Process validation and the subsequent statistical processes. Statistics in process validation is introduced as well as the integration with six sigma and solutions to common mistakes.
This presentation from IVT Network's Method Validation Conference covers required and suggested regulations and guidances for biological process specifications. It also covers dosage form considerations and specifications for other components.
This presentation from the Institute of Validation Technology's 7th Annual Method Validation covers regulatory expectations for deviations and out-of-specification results and protocol exceptions, change control, handing investigations and CAPAs, and avoiding common pitfalls.
In this presentation from IVT's Qualifying and Validating Cloud and Virtualized IT Infrastructures, Chris Wubbolt and John Patterson focus on current trends in cloud computing environments, including aspects of cloud computing and Software-as-a-Service (SaaS) providers that may be of interest to US Food and Drug Administration investigators during an FDA inspection. Important compliance related points to consider for software vendors as they shift to becoming SaaS providers are discussed. The presentation also reviews the pros and cons of cloud computing from a business and compliance perspective, including differences between traditional computing environments and private/public clouds. Examples of issues to consider when using cloud computing environments and SaaS providers are also discussed.
The FDA now defines process validation as “the collection and evaluation of data, from the process design stage throughout production, which establishes scientific evidence that a process is capable of consistently delivering quality products.” On-going process validation is therefore the most important practical outcome of any QbD program. This sessions helps make the connection between process validation and QbD and why QbD starts in process development and doesn’t end in manufacturing.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GMP Systems Integration–Combine Results and Utilize as a Compliance Tool
1. GMP SYSTEMS INTEGRATION –
COMBINE RESULTS AND
UTILIZE AS A COMPLIANCE
TOOL
Betzaida Bigio
Bristol Myers - Squibb
Betzaida Bigio 1
2. We will be Discussing
GMP systems – no definitions
How they interact
Review of recent observations
How they can be integrated to
establish controls
Interactive Exercise
Betzaida Bigio 2
4. Integration Between Systems
Discussion of Recent observations
Classification of observation
Integration between systems based
on each observation
8/30/2012 4
5. Recent Health Authorities
Findings
Discussion of 2011- 2012 Warning letters
Eighteen (18) Warning letters
Focused on Pharmaceutical Industries
cGMP for API (Active Pharmaceutical Ingredient)
cGMP for Finished Pharmaceutical
Location of inspected Sites:
India
China
Germany
Poland
UK
Canada
Mexico
Switzerland
Israel
Japan
US
8/30/2012 5
6. Recent Observations - “Hot”
Topics
Cleaning Validation
Investigations
Media Fill
Laboratory Controls
Test Methods
Environmental Monitoring
Microbiology Contamination Prevention
Disinfectant qualification
Visual Inspection Qualification
Supplier Qualification
Reduce testing
APR, Record Retention
Incoming testing of raw materials 8/30/2012 6
7. Cleaning Validation
Use of two equipment parts for the production of
multiple drug products without validating the process
Process validation for six (6) products conducted
only with one out of two parts
Parts identical in construction but different internal
configurations
Failure to demonstrate are identical
Not cleaned and maintained equipment at appropriate
intervals – holding time
8/30/2012 7
8. Integration Between Systems per
Observation
Validation/Qualification: Controls
Use of two equipment parts for the Equipment qualification
production of multiple drug
products without validating the Process Validation
process
Process validation for six (6) Cleaning validation
products conducted only with
one out of two parts Holding time
Parts identical in construction
but different internal Dirty time
configurations
Systems:
Failure to demonstrate are
identical Change Control
Not cleaned and maintained Validation
equipment at appropriate intervals –
holding time
8/30/2012 8
9. Cleaning Validation
Failure to have in shared manufactured areas, multi-product
equipment:
Well-designed contamination prevention strategy in place
Proper segregation
Or dedicated equipment to a single mfg process
No documented evidence of cleaning between batches or between
product changeovers occurred on non-dedicated equipment
Technology transfer to a facility that was previously used to
manufacture without conducting adequate decontamination,
renovation, and activation of the facility
8/30/2012 9
10. Integration Between Systems per
Observation
Validations/Qualifications: Controls
Failure to have in shared
manufactured areas, multi-product Equipment qualification
equipment:
Process Validation
Well-designed contamination
prevention strategy in place Cleaning validation
Proper segregation
Or dedicated equipment to a Holding time
single mfg process
No documented evidence of cleaning Dirty time
between batches or between product
changeovers occurred on non- Systems:
dedicated equipment Change Control
Technology transfer to a facility that Validation
was previously used to manufacture
without conducting adequate
decontamination, renovation, and
activation of the facility
8/30/2012 10
11. Investigations
Not thoroughly investigated the failure of a batch or any
of its components
Failure to include other batches in investigations
No investigation raw data for a media fill failure
Failure to determine root cause on crystals in the vial
Changes to filling process
Changes to filling needles
Vial washers
8/30/2012 11
12. Integration Between Systems per
Observation
Investigations: Controls
Not thoroughly investigated Product behavior on APR
the failure of a batch or any of
its components Stability
Failure to include other Predictive maintenance
batches in investigations
Preventive maintenance
No investigation raw data for
a media fill failure Systems:
Failure to determine root Investigations
cause on crystals in the vial CAPA
Changes to filling process Supplier
Changes to filling needles Change Control
Vial washers PM’s
8/30/2012 12
13. Investigations
Investigations
Failure to investigate and document contamination
of API
Root cause not determined and production continued
No segregation of impacted lots
Failure to extend investigation to other batches
Contaminated lot release and shipped, then recalled –
failure to have controls in place to identify material
status
Inadequate equipment maintenance program
Firm authorize the use of equipment known to be
defective (10 maintenance requests in one year)
8/30/2012 13
14. Integration Between Systems per
Observation
Investigations: Controls
Failure to investigate and
Product behavior on APR
document contamination of API Stability
Root cause not determined and Materials segregation
production continued
No segregation of impacted lots Supplier’s audit
Failure to extend investigation to Preventive & Predictive
other batches
maintenance
Contaminated lot release and
shipped, then recalled – failure to Systems:
have controls in place to identify Investigations
material status
CAPA
Inadequate equipment maintenance
program Supplier
Firm authorize the use of Change Control
equipment known to be defective Materials
(10 maintenance requests in one
year) PM’s
8/30/2012 14
15. Media Fill
Media fill insufficient to establish that the
aseptic process is in control
Inadequate reconciliation of filled vials
Filled vials not match with incubated vials
Employee who perform critical duties in your aseptic
process did not participate in the simulation process
qualification
8/30/2012 15
16. Integration Between Systems per
Observation
Media Fill: Controls
Media fill insufficient to Manufacturing simulation
establish that the aseptic QC – Microbiology
process is in control Training – Job description, job
Inadequate reconciliation of
duties, SOP’s, employee
filled vials
qualifications, and
Filled vials not match with
incubated vials certifications aligned
Employee who perform Systems:
critical duties in your aseptic Manufacturing
process did not participate in
Training
the simulation process
qualification QC - Microbiology
8/30/2012 16
17. Laboratory Controls
Test Methods
Not established scientifically sound and appropriate
specifications, standards, sampling plans, and test procedures
design to assure that components, in-process materials, and
DP conforms with standards
Validation data for laboratory methods incomplete or not
available
Validation method approved without the complete data in
place
Equipment qualification – all instruments whether newly
purchased or already in use , be qualified prior to being release
for use
8/30/2012 17
18. Integration Between Systems per
Observation
Laboratory Controls: Controls
Test Methods Change Control should establish
Not established scientifically sound specific requirements
and appropriate specifications, Appropriate equipment
standards, sampling plans, and test
procedures design to assure that qualification
components, in-process materials, Documentation approval
and DP conforms with standards
Validation data for laboratory Employee training
methods incomplete or not
available Systems:
Validation method approved Quality Assurance
without the complete data in Quality Control
place
Change Control
Equipment qualification – all instruments
Validations/Qualification
whether newly purchased or already in
use , be qualified prior to being release Training
for use
8/30/2012 18
19. Suppliers Qualification
Reduce testing
Inadequate sampling process if no evidence of vendor
sampling, shipping, and transit process
Incoming testing of raw materials
Not conducted at least one specific identification test
Lack of appropriate validation of the supplier test result
Accept CoA of a stopper supplier without conducting
adequate vendor qualification
No evidence of how your vendor conducts the sampling
(composite, segregation…)
8/30/2012 19
20. Integration Between Systems per
Observation
Supplier’s Qualification: Controls
Reduce testing Material qualification
Inadequate sampling process if Supplier audit
no evidence of vendor sampling, Quality agreement
shipping, and transit process
Testing of components &
Incoming testing of raw materials
material
Not conducted at least one
specific identification test Comparison between CoA and
Lack of appropriate validation of test results
the supplier test result
Systems:
Accept CoA of a stopper supplier
without conducting adequate Quality Assurance
vendor qualification Quality Control
No evidence of how your vendor
conducts the sampling
(composite, segregation…)
8/30/2012 20
21. Shutdown/Start-up
Inadequate aseptic and support area sanitization
following maintenance shutdown
Assure to complete:
Media fill
Smoke studies
QA authorization to resume activities
NO failure on Media fill results (this was the case in the warning
letter, two contaminated units, not adequate investigated root
cause)
8/30/2012 21
22. Integration Between Systems per
Observation
Shutdown/Start-up: Controls
Cleaning
Inadequate aseptic and Change Control should establish
specific requirements
support area sanitization Asceptic Techniques
following maintenance Assure to complete:
shutdown Media fill
Smoke studies
NO failure on Media fill
QA authorization to
results (this was the case resume activities
in the warning letter, two Systems:
contaminated units, not Quality Assurance
adequate investigated Quality Control
Manufacturing
root cause)
8/30/2012 22
23. Microbiology Contamination
Prevention
Disinfectant qualification
Not establish a schedule for the cleaning with agent
design to kills spores – mold found
Disinfectant rotation – efficacy studies not
completed for three of the disinfectant
Failed to demonstrate that is suitable and effective
to remove microorganism from different surfaces
Failure to challenge with multiple organisms
8/30/2012 23
24. Integration Between Systems per
Observation
Microbiology Contamination
Prevention: Controls
Disinfectant qualification Quality Control – Micro
Not establish a schedule for the Robust Qualification of
cleaning with agent design to disinfectant
kills spores – mold found
Disinfectant rotation – efficacy Systems:
studies not completed for three Quality Assurance
of the disinfectant
Quality Control
Failed to demonstrate that is
suitable and effective to Qualification
remove microorganism from
different surfaces
Failure to challenge with
multiple organisms
8/30/2012 24
25. Microbiology Contamination
Prevention
Smoke studies
No evidence of smoke studies
Failure to demonstrate that appropriate design &
controls are in place to prevent turbulence and
stagnant air in critical areas
8/30/2012 25
26. Integration Between Systems per
Observation
Microbiology Contamination
Prevention: Controls
Robust Smoke studies
Smoke studies Air velocities/pressure & air
No evidence of smoke changes data
studies Multidisciplinary team to
Failure to demonstrate evaluate smoke studies
that appropriate design Systems:
Quality Assurance
& controls are in place
Quality Control
to prevent turbulence Engineering
and stagnant air in
critical areas
8/30/2012 26
27. Microbiology Contamination
Prevention
Environmental Monitoring (EM)
Poor routine examination of facilities (mold in class 100 production
Poor condition of walls
Poor aseptic techniques
Personnel sampling areas (hands, chest, gowning, hood, goggles, sleeves)
Gowned employee not monitored by a second qualified person
EM performed at the end of the shift
Operators sanitizing his hands immediately prior to conducting his own
personnel monitoring sampling
Operator spraying his hands directly over the air viable microbial plate. Results
may not reflect microbiology environment of the class 100 room.
8/30/2012 27
28. Integration Between Systems per
Observation
Microbiology Contamination
Prevention: Controls
Environmental Monitoring (EM)
Aseptic techniques
Poor routine examination of facilities Personnel training and
(mold in class 100 production qualification
Poor condition of walls
Poor aseptic techniques Engineering controls
Personnel sampling areas (hands, Facilities walk tru
chest, gowning, hood, goggles,
sleeves) Internal audits
Gowned employee not monitored by a
second qualified person Preventive maintenance
EM performed at the end of the shift Systems:
Operators sanitizing his hands Quality Assurance
immediately prior to conducting his
own personnel monitoring sampling Quality Control
Operator spraying his hands directly Engineering
over the air viable microbial plate. Internal audits
Results may not reflect microbiology
environment of the class 100 room. Training
8/30/2012 28
29. Microbiology Contamination
Prevention
Environmental Monitoring (EM)
EM trends not analyzed – failure to address
increased adverse trends observed
Not establish a schedule for the cleaning with agent design
to kill spores although mold was detected in class 10,000
area
8/30/2012 29
30. Integration Between Systems per
Observation
Microbiology Contamination
Prevention: Controls
Aseptic techniques
Environmental
Monitoring (EM) Personnel training and
qualification
EM trends not analyzed
– failure to address APR
increased adverse Systems:
trends observed Quality Assurance
Not establish a schedule Quality Control
for the cleaning with Training
agent design to kill spores
although mold was
detected in class 10,000
area
8/30/2012 30
31. Visual Inspection
Qualification
Defect in include visual inspection program
Inspectors qualification failure
Visual inspection certification program does not adequately
challenge the technician performing the inspection
SOP should include all possible defects- inspector should be
capable to detect all possible critical defects, challenge vial
selected, and rotated to ensure that each inspector is
challenged to detect each critical defect
8/30/2012 31
32. Integration Between Systems per
Observation
Visual Inspection Qualification: Controls
Defect in include visual inspection Visual Inspection Certification
program Program
Inspectors qualification failure
Personnel training and
Visual inspection certification
program does not adequately qualification
challenge the technician
performing the inspection
SOP should include all possible Systems:
defects- inspector should be
capable to detect all possible Quality Assurance
critical defects, challenge vial Qualification
selected, and rotated to ensure
Training
that each inspector is challenged
to detect each critical defect Manufacturing
8/30/2012 32
33. APR & Record Retention
APR
Quality Unit does not perform an annual evaluation
of the process
This is the process to assure that changes were
effective and the process remains in a validated state
Record Retention
Records destroyed
No evidence of qualification and validation records
resulted in a not validated process, and/or not
qualified equipment
8/30/2012 33
34. Integration Between Systems per
Observation
APR/Record Retention: Controls
APR program in place
APR
Quality Unit does not perform Record Retention based on
an annual evaluation of the criticality and risk
process Change controls,
This is the process to assure that Qualifications/validations -
changes were effective and the never are destroyed
process remains in a validated
state
Record Retention Systems:
Records destroyed Quality Assurance
No evidence of qualification APR
and validation records resulted Validation
in a not validated process, Record Management
and/or not qualified equipment
8/30/2012 34
36. Instructions
Evaluate recent Observations to different systems
and relate each of different GPM Systems
Identify your opportunities
Identify controls that should be in place in each
system to avoid the out of compliance situation and
establish communication among them
Assure that your control address post
implementation sustainability
Identify & avoid Road blocks to maintain
compliance
8/30/2012 36